Valeo Pharma is a Canadian pharmaceutical company established in 2003, specializing in the commercialization of innovative prescription products within Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products. With headquarters in Kirkland, Quebec, Valeo Pharma boasts comprehensive capabilities and infrastructure for product registration and management throughout the commercialization process. The company's commitment to improving healthcare is encapsulated in its slogan: "Providing healthcare professionals and patients with innovative therapeutic solutions to improve quality of life." Their fast growth and dedication to enhancing the quality of life through innovative therapeutic solutions make Valeo Pharma an intriguing prospect for potential investors. As an up-and-coming player in the Canadian pharmaceutical landscape, the company presents an attractive investment opportunity. With a sharp focus on addressing unmet medical needs, Valeo Pharma's strategic positioning within the healthcare industry positions it well for future success. For more insights, please visit www.valeopharma.com.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Debt | $5.00M | 1 | Accord Financial, Inc. (U.S.) | 27 Sep 2023 |
Post-IPO Debt | $580.00K | - | 31 Aug 2023 | |
Post-IPO Equity | $3.92M | - | 31 Aug 2023 | |
Post-IPO Debt | $40.00M | 1 | Sagard Healthcare Royalty Partners | 02 Aug 2022 |
Post-IPO Debt | $25.00M | 1 | 09 Dec 2021 |
No recent news or press coverage available for Valeo Pharma.